Cost of illness of liver diseases in Japan
Cost of illness of liver diseases in Japan
复制标题
日本肝病的费用
DOI：
10.1016/j.aohep.2020.08.073
复制
发表时间：
2021
影响因子：
3.8
通讯作者：
Hasegawa Tomonori
中科院分区：
文献类型：
--
作者：
Matsumoto Kunichika;Wu Yinghui;Fujita Shigeru;Seto Kanako;Hatakeyama Yosuke;Onishi Ryo;Hasegawa Tomonori
前言和目的肝脏疾病的特征是从肝炎进展到肝硬变，然后是肝癌，即随着疾病的进展，死亡率更高的疾病。为估算病毒性肝炎、肝硬变和肝癌等肝病的疾病成本，并确定昂贵但有效的直接作用抗病毒药物对肝病的疾病成本的总体影响。患者或材料和方法利用现有的政府统计数据的疾病成本方法，我们估计了2002-2017年间3年间的经济负担。病毒性肝炎、肝硬变、肝癌的COI呈下降趋势。相反，其他肝病，包括酒精性肝病和非酒精性脂肪性肝炎(NASH)，显示出上升的趋势。2014-2017年间，尽管药品单价大幅上涨，丙型肝炎的COI仍在继续下降。结论日本肝病的COI在过去15年里一直在下降。未来，丙型肝炎患者的数量有望进一步减少，即使NASH和酒精性肝病的发病率增加，肝硬变和肝癌的发病率也可能继续下降。
Introduction and objectivesLiver disease is characterized by the progression from hepatitis to cirrhosis, followed by liver cancer, i.e., a disease with a higher mortality rate as the disease progresses. To estimate the cost of illness (COI) of liver diseases, including viral hepatitis, cirrhosis, and liver cancer, and to determine the overall effect of expensive but effective direct-acting antivirals on the COI of liver diseases.Patients or materials and methodsUsing a COI method from available government statistics data, we estimated the economic burden at 3-year intervals from 2002 to 2017.ResultsThe total COI of liver diseases was 1402 billion JPY in 2017. The COI of viral hepatitis, cirrhosis, and liver cancer showed a downward trend. Conversely, other liver diseases, including alcoholic liver disease and nonalcoholic steatohepatitis (NASH), showed an upward trend. The COI of hepatitis C continued to decline despite a sharp increase in drug unit prices between 2014 and 2017.ConclusionsThe COI of liver diseases in Japan has been decreasing for the past 15 years. In the future, a further reduction in patients with hepatitis C is expected, and even if the incidence of NASH and alcoholic liver disease increases, that of cirrhosis and liver cancer will likely continue to decrease.